A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Solid Tumors
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:

    1. Patients must have histological or cytological evidence of a solid tumor; for the dose expansion portion of the study, the subject has histological or cytological evidence of 1 of the selected solid tumor types, including melanoma, renal cell carcinoma, NSCLC, bladder cancer, ovarian cancer, and triple negative breast cancer.

     

    2. Patients must have failed to respond to established therapies known to provide clinical benefit for the malignancy in question, or be intolerant of established therapies known to provide clinical benefit for the malignancy in question.

     

    3. Patients may have been treated with prior immunotherapy.


You may not be eligible for this study if the following are true:

  • 1.  Pregnancy or lactation

     

    2.  Patients with active or symptomatic central nervous system metastases

     

    3.  Patients with known hypersensitivity to any components of ALKS 4230

     

    4.  Patients who require pharmacologic doses of corticosteroids




If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.